#1 Clinical Trials Search in Europe

Flecainide Acetate

Flecainide Acetate, a medication primarily used for heart rhythm disorders, has been the subject of several clinical trials exploring its potential in various cardiac conditions. These trials have investigated its effectiveness in treating atrial fibrillation, neuropathic pain, and a rare genetic heart condition called Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT). The studies have examined different administration methods, dosages, and combinations with other treatments to optimize its use and understand its full potential in managing these conditions.

Table of Contents

What is Flecainide Acetate?

Flecainide Acetate, also known by its brand name FlecIH, is a medication primarily used to treat various heart rhythm disorders[1]. It belongs to a class of drugs called antiarrhythmics, which help regulate the heart’s electrical activity. Flecainide works by slowing down the electrical signals in the heart, which can help restore a normal heart rhythm in certain conditions.

Medical Uses of Flecainide

Flecainide is used to treat several heart-related conditions:

  • Paroxysmal Atrial Fibrillation (PAF): This is a type of irregular heartbeat that comes and goes. Flecainide can help convert the heart back to its normal rhythm[1].
  • Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT): This is a rare genetic condition that can cause a dangerously fast heart rate. Flecainide has shown promise in treating this condition[3].
  • Chronic Neuropathic Pain: Some studies have explored the use of flecainide in managing chronic pain, particularly in patients with cancer or AIDS[2].

How Flecainide is Administered

Flecainide can be administered in different ways, depending on the condition being treated:

  • Oral tablets: The most common form, taken by mouth as prescribed by a doctor[2].
  • Inhalation solution: A newer method being studied for rapid treatment of atrial fibrillation. This involves breathing in the medication through a nebulizer, a device that turns liquid medicine into a fine mist[1].

The dosage and frequency of flecainide administration can vary depending on the specific condition and the patient’s response to the medication. Always follow your doctor’s instructions carefully.

Recent Clinical Trials

Several clinical trials have been conducted to explore new uses and administration methods for flecainide:

  • INSTANT Trial: This study investigated the use of inhaled flecainide to quickly convert recent-onset atrial fibrillation back to normal heart rhythm. The trial explored different dosing regimens and the possibility of patient self-administration under medical supervision[1].
  • Chronic Neuropathic Pain Study: A Phase II trial examined the effectiveness of flecainide in managing chronic neuropathic pain in patients with cancer or AIDS[2].
  • CPVT Trial: A crossover study tested whether adding flecainide to standard therapy (beta-blockers) could reduce abnormal heart rhythms during exercise in patients with Catecholaminergic Polymorphic Ventricular Tachycardia[3].

Potential Side Effects and Monitoring

As with any medication, flecainide can cause side effects. Some potential effects that have been monitored in clinical trials include:

  • Changes in heart rhythm: Doctors may use ECG (electrocardiogram) recordings to monitor the heart’s electrical activity and ensure the medication is working correctly[1].
  • Blood levels: In some cases, blood tests may be done to check the concentration of flecainide in your body[3].

It’s important to note that the safety and effectiveness of flecainide can vary depending on the individual and the condition being treated. Always discuss potential risks and benefits with your healthcare provider.

Trial Name Condition Administration Method Key Outcomes Measured
INSTANT (NCT03539302) Paroxysmal Atrial Fibrillation Oral Inhalation Solution Conversion to sinus rhythm, pharmacokinetics, ECG changes
NCT00002996 Chronic Neuropathic Pain Oral Capsules Pain reduction using Brief Pain Inventory
NCT01117454 Catecholaminergic Polymorphic Ventricular Tachycardia Oral (with dose titration) Reduction in ventricular ectopy during exercise testing

FAQ

  • What is Flecainide Acetate used for in clinical trials? Flecainide Acetate has been studied in clinical trials for various conditions, including atrial fibrillation, chronic neuropathic pain, and Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT). It's primarily used to treat heart rhythm disorders.
  • How is Flecainide Acetate administered in these trials? In the trials, Flecainide Acetate was administered in different ways. For atrial fibrillation, it was given as an oral inhalation solution using a nebulizer. In the neuropathic pain study, it was given orally in capsule form. For CPVT, it was administered orally with the dose adjusted to achieve specific blood levels.
  • What is the INSTANT trial studying about Flecainide Acetate? The INSTANT trial is studying the use of inhaled Flecainide Acetate to convert recent onset symptomatic atrial fibrillation to normal sinus rhythm. It's exploring different dosing regimens and the feasibility of patient-led self-administration.
  • How is Flecainide Acetate being used in the CPVT trial? In the CPVT trial, Flecainide Acetate is being added to standard therapy (beta-blockers) to see if it can reduce ventricular ectopy (irregular heartbeats) during exercise testing compared to placebo plus standard therapy.
  • What are some of the outcomes being measured in these Flecainide Acetate trials? The trials are measuring various outcomes, including the percentage of patients converting from atrial fibrillation to normal sinus rhythm, changes in pain levels for neuropathic pain, and the number of patients experiencing ventricular ectopy or ventricular tachycardia during exercise testing for CPVT.

Ongoing Clinical Trials on Flecainide Acetate

  • Study of drug combination therapy for prevention of recurrent stroke in patients with acute ischemic stroke and atrial fibrillation

    Recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Germany The Netherlands Spain

  • Study on Flecainide and Amiodarone for Treating Atrial Fibrillation in Patients with Coronary Artery Disease and Ejection Fraction Over 35%

    Not recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Greece

  • Study on Flecainide and Ranolazine for Restoring Heart Rhythm in Patients with Recent Atrial Fibrillation

    Not recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Greece

Glossary

  • Atrial Fibrillation (AF): A heart rhythm disorder characterized by irregular and often rapid heartbeat in the upper chambers of the heart (atria).
  • Sinus Rhythm (SR): The normal heart rhythm, where electrical signals start in the sinoatrial node and travel through the heart in an organized way.
  • Paroxysmal Atrial Fibrillation (PAF): A type of atrial fibrillation that starts suddenly and stops on its own within 7 days.
  • Neuropathic Pain: Pain caused by damage or disease affecting the nervous system, often described as burning, shooting, or electric-like sensations.
  • Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT): A rare genetic heart condition that can cause a dangerously fast heart rhythm in response to physical or emotional stress.
  • Ventricular Ectopy: Extra, abnormal heartbeats that start in the lower chambers of the heart (ventricles).
  • Electrocardiogram (ECG): A test that records the electrical activity of the heart.
  • Pharmacokinetics (PK): The study of how a drug moves through the body, including its absorption, distribution, metabolism, and excretion.
  • Pharmacodynamics (PD): The study of how a drug affects the body, including its mechanism of action and relationship between drug concentration and effect.
  • Beta-blockers: A class of medications that block the effects of adrenaline and related hormones, often used to treat heart conditions and high blood pressure.

References

  1. https://clinicaltrials.gov/study/NCT03539302
  2. https://clinicaltrials.gov/study/NCT00002996
  3. https://clinicaltrials.gov/study/NCT01117454